Drug transport to brain with targeted nanoparticles

Area of Science:

• Nanomedicine and Drug Delivery
• Neuroscience
• Biotechnology

Background:

• Nanoparticles require specific transport mechanisms to cross the blood-brain barrier (BBB).
• Current nanoparticle formulations like polysorbate 80-coated polybutylcyanoacrylate nanoparticles have limitations for clinical brain drug delivery.
• Long-circulating nanoparticles, such as methoxypoly(ethylene glycol)-polylactide (mPEG-PLA) or poly(lactide-co-glycolide) (PLGA), offer improved safety and sustained release.

Purpose of the Study:

• To review the properties and preparation methods of brain-targeted nanoparticles.
• To highlight the potential of pegylated immunonanoparticles for effective drug delivery across the BBB.
• To discuss limitations of current nanoparticle systems and advancements in targeted delivery.

Main Methods:

• Review of existing literature on nanoparticle drug carriers for brain delivery.
• Discussion of receptor-mediated transport mechanisms across the BBB.
• Analysis of nanoparticle properties including structure, loading capacity, and pharmacokinetics.
• Overview of methods for synthesizing brain-targeted pegylated immunonanoparticles.

Main Results:

• Polysorbate 80-coated nanoparticles show promise but have debated mechanisms and limitations.
• mPEG-PLA/PLGA nanoparticles offer good safety and sustained drug release.
• Functionalized PEG-PLA enables targeted nanoparticle preparation via ligand conjugation.
• Pegylated immunonanoparticles utilizing peptidomimetic antibodies can target BBB receptors for enhanced brain delivery.

Conclusions:

• Pegylated immunonanoparticles represent a promising strategy for delivering therapeutics into the brain parenchyma.
• These targeted nanoparticles aim to bypass BBB limitations without compromising its integrity.
• Further development and characterization of immunonanoparticles are crucial for clinical translation in treating brain disorders.